Total Value in 2011: $13,545.95M*

Number of Deals in 2011: 143


Company (Location)

Company (Location)

Value (M)

Type/Product Area

Terms/Details (Date)


JUNE

Affectis Pharmaceuticals AG (Munich, Germany)

Merck Serono (division of Merck KgaA; Darmstadt, Germany)

$407.5

Deal to develop neurology compounds targeting P2X7 receptors, a calcium channel thought to play a role in neuroprotection

The deal gives Merck worldwide rights to develop and commercialize the compounds in exchange for $3.5M up front, plus research funding, with a potential $404M in milestones, plus royalties (6/9)

Audion Therapeutics (Amsterdam, the Netherlands)

Sanofi-Aventis SA (Paris)

ND

Two-year research collaboration to develop potential treatments for hearing loss through the optimization of small molecules by using a regenerative medicine approach

Sanofi has an option to license technology rights from Audion (6/17)

AVEO Pharmaceuticals Inc. (Cambridge, Mass.)

Centocor Ortho Biotech Inc. (Horsham, Pa.; unit of Johnson & Johnson)

$555

Exclusive worldwide development and commercialization deal to AVEO's preclinical antibodies targeting the RON receptor

Centocor paid $15M up front, and will pay as much as $540M in milestones, plus double-digit royalties on worldwide net sales (6/1)

BioMarin Pharmaceutical Inc. (Novato, Calif.)

Pfizer Inc. (New York)

$48.5

Purchase of a bulk biologics manufacturing plant in Cork, Ireland from Pfizer

BioMarin paid $48.5M for the plant, which will produce enzyme replacement therapy GALNS, as well as other products (6/24)

BioPontis Alliance LLC (Raleigh, N.C.)

Janssen Biotech Inc. (Horsham, Pa.; formerly Centocor Ortho Biotech Inc.; part of Johnson & Johnson)

ND

Translational Research Agreement for drug development

BioPontis will receive input and guidance to ensure its early programs are aligned with market demand; Janssen will have access to evaluate and license early stage therapeutic opportunities (6/30)

Biotest AG ( Dreieich, Germany)

Abbott (Abbott Park, Ill.)

$480

Autoimmune disease deal focused on BT-061 for rheumatoid arthritis and psoriasis

Biotest gets $85M up front and is eligible for $395M in milestones, plus royalties on worldwide sales, except in Europe, where the companies will co-promote BT-061 (6/22)

Clovis Oncology Inc. (Boulder, Colo.)

Pfizer Inc. (New York)

$255

Deal for the right to develop and commercialize PF-01367338, an inhibitor of Poly ADP-ribose polymerase inhibitor, which is in Phase I/II development for solid tumors

Clovis will pay an undisclosed up-front fee to Pfizer, plus potential milestones of $255M; Pfizer Venture Investments will make an equity investment in Clovis (6/6)

Clovis Oncology Inc. (Boulder, Colo.)

Roche AG (Basel, Switzerland)

ND

Partnership to develop a PCR-based companion diagnostic test for epidermal growth factor receptor mutations in non-small-cell lung cancer

The test is being developed to support CO-1686, which targets the T790M mutant form of EGFR (6/3)

Cortex Pharmaceuticals Inc. (Irvine, Calif.)

Servier (Paris)

$1

Agreement to sell rights to CX1632 to Servier for an up-front payment of $1M

The companies will remain joint owners of related patents; in the event that Servier opts to acquire sole ownership of patent rights to CX1632, it will pay Cortex an additional $2M (6/14)

Evotec AG (Hamburg, Germany)

Roche AG (Basel, Switzerland)

ND

Collaboration to identify appropriate pharmacodynamics and protein-activity-based patient stratification biomarkers for Roche's oncology drugs

Evotec will use its phosphoScout platform to discover protein-phosphorylations, while Roche will conduct clinical trials and assess the development of companion diagnostics (6/27)

Gilead Sciences Inc. (Foster City, Calif.)

Johnson & Johnson (New Brunswick, N.J.)

ND

License agreement to develop and commercialize a fixed-dose combination of Gilead's Phase III boosting agent cobicistat and Tibotec's Prezista for HIV

Tibotec will be responsible for the formulation, manufacturing, registration, distribution and commercialization of the combination product worldwide (6/29)

Hanwha Chemical Corp. (Seoul, South Korea)

Merck and Co. Inc. (Whitehouse Station, N.J.)

ND

Development and commercialization agreement for a biosimilar form of Enbrel

Merck made an undisclosed up-front payment to Hanwha, with possible additional milestone payments and tiered royalties on product sales (6/14)

Heptares Therapeutics Ltd. (Welwyn Garden City, UK)

AstraZeneca plc (London)

$6.25

Four-year collaboration focused on discovery and development of new medicines for the treatment of central nervous system, metabolic and other diseases targeting G-protein coupled receptors

Heptares will receive an up-front $6.25M cash payment plus committed research funding and potential milestone payments and royalties (6/1)

Neuralstem Inc. (Rockville, Md.)

Summit Pharmaceuticals International Corp. (Tokyo)

ND

Licensing agreement for its depression candidate, NSI-189

The agreement gives SPI the right to market development and licensing rights to the drug (6/8)

PTC Therapeutics Inc. (South Plainfield, N.J.)

AstraZeneca plc (London)

ND

Partnership for its Gene Expression Modulation by Small-molecules drug discovery platform; initially focused on oncology but could encompass up to eight targets across different therapeutic areas

PTC will get an undisclosed amount of money from an up-front cash payment, committed research funding, milestone payments and royalties; PTC has an option to participate in the development of select product candidates (6/30)

Sirnaomic Inc. (Gaithersburg, Md.)

Guangdong Zhongsheng Pharmaceutical Co. Ltd. (Dongguan City, China)

$9.75

Partnership to develop small interfering RNA for diabetic retinopathy and age-related macular degeneration

The partnership will focus on clinical development and commercialization of STP601; Guangdong will commit $9.75M including up-front and milestone payments, and Sirnaomics also will be eligible for royalty sharing (6/24)

Unigene Laboratories Inc. (Boonton, N.J.)

China Pharmaceutical Group Ltd. (Hong Kong)

$1.05

Deal to sell its 45% equity interest in Chinese joint venture Unigene Biotech-nology Co. Ltd. to China Pharmaceutical Group or one of its affiliates for $1.05M

All technology licenses, sublicenses and other rights granted to the joint venture and China Pharmaceutical Group have been returned to Unigene; the venture was originally formed in June 2000 (6/14)

Zealand Pharma A/S (Copenhagen, Denmark)

Boehringer Ingelheim GmbH (Ingelheim, Germany)

$537.3

Licensing agreement for exclusive global development and commercialization rights to its lead glucagon-GLP-1 dual agonist drug candidate, ZP2929 to treat Type II diabetes and obesity

Zealand could earn as much as $537.3M in milestone and other payments, including $57.76M during the first two years (6/17)

JULY

Array BioPharma Inc. (Boulder, Colo.)

Aslan Pharmaceuticals Pte Ltd. (Singapore)

ND

License agreement to develop Array's HER2/EGFR inhibitor, ARRY-543, currently starting Phase II development for solid tumors

Aslan will fund and develop it through proof of concept, intitially targeting patients with gastric cancer through a program conducted in Asia; if proof of concept is achieved, Aslan will identify a global partner for Phase III development and commercialization (7/14)

Astellas Pharma Inc. (Tokyo)

Royalty Pharma (New York)

$609

Astellas sold its IP assets relating to Prosidion's dipeptidyl peptidase IV inhibitors for Type II diabetes

Royalty Pharma paid $609M and will now receive all royalty payments and milestones (7/5)

Cambrex Corp. (East Rutherford, N.J.)

Tillotts Pharma AG (Rheinfelden, Switzerland)

ND

Development and commercialization agreement for a mesalamine-based technology for use in the treatment of inflammatory bowel disease

Tillotts acquired the worldwide exclusive rights to develop and commercialize products based on Cambrex' 5-ASA-based technology in exchange for undisclosed milestone payments, as well as royalties (7/7)

Innate Pharma SA (Marseilles, France)

Bristol-Myers Squibb Co. (Princeton, N.J.)

$465

Collaboration for exclusive worldwide rights to IPH2102, as well as to related compounds designed to block KIR receptors, for all potential indications

Innate will receive $35M up front, and BMS will fund work on IPH2102 and agreed to pay up to $430M in development and commercialization milestones, plus tiered, double-digit royalties on worldwide net sales (7/7)

MediciNova Inc. (San Diego)

Zhejiang Medicine Co. Ltd. (Hangzhou, China)

ND

Joint venture to develop and commercialize MediciNova's MN-221 in China

The product is in development to treat acute exacerbations of asthma and chronic obstructive pulmonary disease (7/5)

MingSight Pharmaceuticals (Taizhou, China)

Shenzen Relin Medicin (Shenzen, China)

ND

Joint venture to develop and commercialize a therapy for diabetic eye disease in China

The new venture, MingSight-Relin, will advance MS-533 (7/7)

Pharmasset Inc. (Princeton, N.J.)

Tibotec Pharmaceuticals Inc. (Raritan, N.J.)

ND

Collaboration to evaluate its nucleotide polymerase inhibitor PSI-7977 in combination with Tibotec's protease inhibitor TMC435 in a Phase II study in chronic hepatitis C virus

Financial terms were not disclosed (7/7)

Rib-X Pharmaceuticals Inc. (New Haven, Conn.)

Sanofi SA (Paris)

$763

Exclusive worldwide research collaboration and licensing option for antibiotics resulting from its RX-04 program to treat resistant Gram-positive and resistant Gram-negative pathogens

Rib-X will receive $10M in an up-front payment and is eligible to receive up to an additional $9M in near-term research-based milestones, plus up to $86M in development and regulatory milestones, and more than $100M for commercial milestones, for a minimum of four target product profiles; total milestones could reach $744M (7/7)

Vical Inc. (San Diego)

Astellas Pharma Inc. (Tokyo)

$130

License agreement for worldwide development and commercialization of Vical's TransVax vaccine for cytomegalovirus reactivation in hematopoietic stem cell transplant and solid organ transplant recipients

Vical will get $25M up front and $10M more when design of a Phase III trial is completed; milestone payments of $95M could bring the total to $130M through launch, and Vical also could receive double-digit royalties (7/18)


Notes:

The date indicated refers to the BioWorld Today issue in which the news item can be found.

* The total value represents the amount of disclosed money involving collaborations between biotechnology and pharmaceutical companies, including manufacturing, marketing and distribution agreements detailed in the following chart.

** Denotes the date the item ran in BioWorld International.